Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy

Area of Science:

• Immunotherapy
• Cellular Therapy
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary immunotherapy.
• CAR-T cells targeting CD19 or B cell maturation antigens have shown success in hematologic malignancies.
• Challenges hinder CAR-T cell therapy for solid tumors, including antigen heterogeneity and the immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To review advances in CAR-T cell engineering.
• To discuss strategies for overcoming challenges in solid tumor treatment.
• To highlight the potential of CAR-T cell therapy in autoimmune diseases.

Main Methods:

• Review of current literature on CAR-T cell therapy.
• Discussion of DNA- and mRNA-based platforms for CAR-T cell programming (ex vivo and in vivo).
• Exploration of strategies to improve CAR-T cell trafficking, persistence, and TME resistance.

Main Results:

• CAR-T cell therapy has achieved significant remission rates in hematologic malignancies.
• CAR-T cells show potential for treating autoimmune diseases like systemic lupus erythematosus.
• Advances in CAR-T cell engineering are being made for various applications.

Conclusions:

• CAR-T cell therapy is a powerful tool in oncology and shows promise in autoimmune diseases.
• Overcoming solid tumor challenges requires enhanced CAR-T cell engineering and TME modulation.
• Future directions involve optimizing CAR-T cell function for broader therapeutic applications.